Delivery Order SPE2DB25D3110-SPE2DB25FTCGD
Award Date
1/15/25
Potential Completion Date
1/16/25
Potential Value
$1.1K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $4,401.60, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Vyvanse 30 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Firm Fixed Price Delivery Order, with an ultimate completion date of April 18, 2025. This contract is not set aside for any specific business type. AmerisourceBergen Drug Corp...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $30,739.63 firm fixed-price contract is for the delivery of Vyvanse capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is not set aside and has an ultimate completion date of April 18, 2025. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,638.64 firm fixed-price delivery order is for the supply of Vyvanse 10 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has an ultimate completion date of November 4, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 100 capsules of Vyvanse 30 mg, a medication used to treat attention deficit hyperactivity disorder (ADHD). The contract is a Firm Fixed Price Delivery Order with a ceiling value of $1,783.60 and a performance period ending on June 6, 2025. The contract is not set aside for any specific...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $3,148.38, is for the supply of Vyvanse 10 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 17, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA), a defense agency. The contract is for the delivery of Vyvanse 60 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has a ceiling value of $1,442.99 and a completion date of June 26, 2025. It is a firm-fixed-price delivery order contract, with no set-aside designation, indicating open competition....
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,224.10 delivery order contract is for the supply of Vyvanse 30 mg capsules, a prescription medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has an ultimate completion date of November 20, 2024 and is structured as a firm-fixed price delivery order. This award is associated...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,816.33, is for the delivery of Vyvanse 30 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has a period of performance through November 18, 2024 and is a firm fixed-price contract. This contract is not designated as a set-aside. AmerisourceBergen holds a larger Indefinite...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,783.60, is for the delivery of Vyvanse 10 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a firm-fixed-price contract with an ultimate completion date of January 2, 2025. This contract is part of a larger Indefinite Delivery...
This is a $1,337.70 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Vyvanse 10 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has an ultimate completion date of June 27, 2025 and is not set aside for any specific business category. AmerisourceBergen Drug Corp holds a...